Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.

ABSTRACT:

Background

Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) and the effect of dapagliflozin on markers of iron metabolism. We also analyzed the effect of dapagliflozin on outcomes, according to iron status at baseline.

Methods

Iron deficiency was defined as a ferritin level <100 ng/mL or a transferrin saturation <20% and a ferritin level 100 to 299 ng/mL. Additional biomarkers of iron metabolism, including soluble transferrin receptor, erythropoietin, and hepcidin were measured at baseline and 12 months after randomization. The primary outcome was a composite of worsening heart failure (hospitali

SUBMITTER: Docherty KF 

PROVIDER: S-EPMC9508991 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature